Rational development of histone deacetylase inhibitors as anticancer agents: A review

被引：197

作者：

Acharya, MR

Sparreboom, A

Venitz, J

Figg, WD

机构：

[1] NCI, NIH, Bethesda, MD 20892 USA

[2] Virginia Commonwealth Univ, Dept Pharmaceut, Sch Pharm, Richmond, VA USA

来源：

MOLECULAR PHARMACOLOGY | 2005年 / 68卷 / 04期

关键词：

D O I：

10.1124/mol.105.014167

中图分类号：

R9 [药学];

学科分类号：

1007 [药学];

摘要：

The epigenome is defined by DNA methylation patterns and the associated post-translational modifications of histones. This histone code determines the expression status of individual genes dependent upon their localization on the chromatin. The histone deacetylases (HDACs) play a major role in keeping the balance between the acetylated and deacetylated states of chromatin and eventually regulate gene expression. Recent developments in understanding the cancer cell cycle, specifically the interplay with chromatin control, are providing opportunities for developing mechanism-based therapeutic drugs. Inhibitors of HDACs are under considerable exploration, in part because of their potential roles in reversing the silenced genes in transformed tumor cells by modulating transcriptional processes. This review is an effort to summarize the nonclinical and clinical status of HDAC inhibitors currently under development in anticancer therapy.

引用

页码：917 / 932

页数：16

共 238 条

[1]

Annunziato AT, 2000, GENE EXPRESSION, V9, P37

[2]

p21WAF1 is required for butyrate-mediated growth inhibition of human colon cancer cells [J].

Archer, SY ;

Meng, SF ;

Shei, A ;

Hodin, RA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (12) :6791-6796

[3]

Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein [J].

Aron, JL ;

Parthun, MR ;

Marcucci, G ;

Kitada, S ;

Mone, AP ;

Davis, ME ;

Shen, TS ;

Murphy, T ;

Wickham, J ;

Kanakry, C ;

Lucas, DM ;

Reed, JC ;

Grever, MR ;

Byrd, JC .

BLOOD, 2003, 102 (02) :652-658

[4]

Histone deacetylase inhibitors: From chromatin remodeling to experimental cancer therapeutics [J].

Arts, J ;

de Schepper, S ;

Van Emelen, K .

CURRENT MEDICINAL CHEMISTRY, 2003, 10 (22) :2343-2350

[5]

Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824 [J].

Atadja, P ;

Gao, L ;

Kwon, P ;

Trogani, N ;

Walker, H ;

Hsu, M ;

Yeleswarapu, L ;

Chandramouli, N ;

Perez, L ;

Versace, R ;

Wu, A ;

Sambucetti, L ;

Lassota, P ;

Cohen, D ;

Bair, K ;

Wood, A ;

Remiszewski, S .

CANCER RESEARCH, 2004, 64 (02) :689-695

[6]

ATADJA P, 2004, NOVART FDN SYMP, V259, P266

[7]

ATADJA P, 2004, NOVART FDN SYMP, V259, P285

[8]

Atadja Peter, 2004, Novartis Found Symp, V259, P249

[9]

ATMACA A, 2004, J CLIN ONCOL S, V22

[10]

Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3 [J].

Bali, P ;

George, P ;

Cohen, P ;

Tao, JG ;

Guo, F ;

Sigua, C ;

Vishvanath, A ;

Scuto, A ;

Annavarapu, S ;

Fiskus, W ;

Moscinski, L ;

Atadja, P ;

Bhalla, K .

CLINICAL CANCER RESEARCH, 2004, 10 (15) :4991-4997

← 1 2 3 4 5 6 7 8 9 10 →